Search
for
Sort by
Research 31–60 of 141
- TREATMENT PEARLS FROM EUROPE
- Unveiling Post-COVID-19 syndrome: incidence, biomarkers, and clinical phenotypes in a Thai population
- 51223 A novel human disease model of alopecia areata to evaluate benefit of the DHODH inhibitor farudodstat
- Italian National Registry of Alopecia Areata: an epidemiological study of 699 Italian patients
- 90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse
- LB1777 A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis.
- Sensitive scalp: An epidemiologic study in patients with hair loss
- In Vitro and Ex Vivo Hair Follicle Models to Explore Therapeutic Options for Hair Regeneration
- 613 Assessment of the induction and morphogenic potential of human hair matrix cells and dermal papilla fibroblasts ex vivo
- Effect of Orthosiphon stamineus plant extract on in vitro dermal papilla cell proliferation and ex vivo hair growth
- Melasma and Endocrine Disorders
- Treatment With Ashwagandha‐Derived Exosome‐Like Nanovesicles Up‐Regulates VEGF ‐A Production and Promotes Human Hair Growth Ex Vivo
- Bridging Dermatology and Cardiology: The Link between Skin Lesionsand Cardiovascular Risk
- Application of a novel ingredient Blend promotes hair growth by modulating Wnt/β‐catenin signaling, DP inductivity, and boosting elastin expression in healthy human scalp hair follicles ex vivo
- Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata
- Image 1_Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata.pdf
- Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study
- Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment—A Single Center Case Series
- Can we identify a post‐Serenoa syndrome (PSS)? A case series on sexual and psychiatric side effects of <i>Serenoa repens</i>
- Fast clinical response with topical ruxolitinib in the management of non-segmental vitiligo detected by VISIA<sup>®</sup> analysis system
- 046 Analysing the mechanistic basis of Ritlecitinib’s therapeutic effects in Alopecia Areata
- 460 Promotion of Hair Growth in Ex Vivo Human Scalp Hair Follicles by the Novel Ingredient Blend NUL-5: Enhancing Elastin Expression and Wnt Signaling Activation
- 186 Mechanistic insights into Ritlecitinib-mediated immunomodulation in Alopecia Areata
- 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
- Profibrotic Molecules Are Reduced in CRISPR-Edited Emery–Dreifuss Muscular Dystrophy Fibroblasts
- Postnatal determinants of testicular germ cell tumor by histological subtypes: The EPSAM1 and EPSAM2 studies
- 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
- Alopecia in Female Athletes Using Androgenic and Anabolic Steroids: Pathophysiology and Management
- Adrenal causes of endocrine hypertension in childhood or adolescence